Long-term outcomes and prognostic factors in generalized myasthenia gravis.

Yukiko OzawaAkiyuki UzawaManato YasudaYuta KojimaYosuke OnishiFumiko OdaTetsuya KanaiKeiichi HimuroNaoki KawaguchiSatoshi Kuwabara

Published in: Journal of neurology (2021)

Approximately 60% of the MG patients achieved the treatment goal within 2 years after treatment. PSL dose and the cumulative number of plasmapheresis procedures at 3 months after immunotherapy initiation may help identify treatment-resistant patients with MG.

Keyphrases

prognostic factors
myasthenia gravis
end stage renal disease
newly diagnosed
ejection fraction
patient reported outcomes
smoking cessation
patient reported